Passage Bio Inc PASG.OQ PASG.O is expected to show no change in quarterly revenue when it reports results on March 3 (estimated) for the period ending December 31 2024
LSEG's mean analyst estimate for Passage Bio Inc is for a loss of 20 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Passage Bio Inc is $5.50, above its last closing price of $0.51.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Sep. 30 2024 | -0.21 | -0.23 | -0.31 | Missed | -34.8 |
Jun. 30 2024 | -0.31 | -0.31 | -0.26 | Beat | 16.1 |
Mar. 31 2024 | -0.36 | -0.36 | -0.30 | Beat | 16.1 |
Dec. 31 2023 | -0.40 | -0.40 | -0.30 | Beat | 25.3 |
Sep. 30 2023 | -0.47 | -0.46 | -0.49 | Missed | -7.4 |
Jun. 30 2023 | -0.47 | -0.48 | -0.44 | Beat | 8 |
Mar. 31 2023 | -0.50 | -0.50 | -0.63 | Missed | -27.2 |
Dec. 31 2022 | -0.51 | -0.52 | -0.49 | Beat | 6.3 |
This summary was machine generated February 28 at 13:32 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。